Boston Scientific Corporation (BSX)
After hours:
| Previous close | 67.42 |
| Open | 67.87 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1000 |
| Day's range | 66.90 - 68.08 |
| 52-week range | 48.35 - 69.21 |
| Volume | |
| Avg. volume | 6,331,682 |
| Market cap | 98.968B |
| Beta (5Y monthly) | 0.79 |
| PE ratio (TTM) | 62.93 |
| EPS (TTM) | 1.07 |
| Earnings date | 24 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 73.75 |
ZacksUnveiling Boston Scientific (BSX) Q1 Outlook: Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Boston Scientific (BSX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
- Reuters
UPDATE 1-FDA classifies recall of Boston Scientific device as 'most serious'
The U.S. Food and Drug Administration on Wednesday classified a recall of Boston Scientific's device used to block blood flow during excessive bleeding or hemorrhaging as "most serious". An investigation showed that Boston's device, Obsidio Embolic, when used with a specific technique posed a higher risk of bowel ischemia during procedures to stop gastrointestinal (GI) bleeding, the agency said. Bowel ischemia describes disorders that occur when blood flow to your intestines decrease, causing severe abdominal pain.
ZacksWhat's in Store for Boston Scientific (BSX) in Q1 Earnings?
Boston Scientific (BSX) is expected to have registered strong growth in the Asia Pacific, led by strength in China, Japan and Latin America.
